1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

exclusivity gains shadow over Glenmark US Locoid generic launch

 
• By Anju Ghangurde

Glenmark Generics has launched its generic version of Astellas Pharma/Triax Pharmaceuticals' eczema treatment, Locoid Lipocream (0.1% hydrocortisone butyrate cream), on the US market, even as the contested presence of an authorized generic version is expected to take some sheen off the first-to-file opportunity.

Glenmark Generics has launched its generic version of Astellas Pharma/Triax Pharmaceuticals' eczema treatment, Locoid Lipocream (0.1% hydrocortisone butyrate cream), on the US market, even as the contested presence of an authorized generic version is expected to take some sheen off the first-to-file opportunity.

Glenmark, which is entitled to 180-days of exclusivity being the first to file an ANDA for the product, had earlier...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 
• By Anju Ghangurde

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By Kevin Grogan

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By Manas Mishra

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

More from Therapy Areas

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By Aakash Babu

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.

Dispatch Uses ‘Flare’ To Send CAR-Ts To Solid Tumors

 
• By Alaric DeArment

With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.

Where Next For Biologics In COPD After Roche’s Astegolimab Phase III Missfire?

 
• By Sushmita Panda

The Phase III failure could dent Roche’s hopes of entering the COPD market with its novel therapy, despite its success in a large Phase IIb trial. It also marks another disappointment for the anti-IL33/ST2 approach.